Drug intelligence / Profile preview

RIST472

Development stage: Unknown
Lead developer: Aristea Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

RIST472 is a mid-stage oral small molecule developed by Arena Pharmaceuticals and Aristea Therapeutics. It targets the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTh2), also known as Prostaglandin D2 receptor 2 (DP2), and was intended for the treatment of immunologic conditions. The drug was later discontinued by Pfizer following its acquisition of Arena Pharmaceuticals.

Targets

CXCR2 (C-X-C Motif Chemokine Receptor 2)

Beyond the preview

Go deeper on RIST472.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIST472.

Explore the full profile